Susunod

Auto-play

Dr. Andrew Brohl at ASCO 2023: Abstract No. 9534

2 Mga view • 07/17/23
Ibahagi
I-embed
administrator
administrator
Mga subscriber
0

At ASCO 2023, Moffitt's Dr. Andrew Brohl discusses a phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Magpakita ng higit pa
0 Mga komento sort Pagbukud-bukurin Ayon
Mga Komento sa Facebook

Susunod

Auto-play